PRISMA Checklist for the Meta-analysis
Use documented guidelines to guide dosage planning decisions
Theoretical synergy: three pathways working together Triple-pathway hypothesis: Why it might work: Non-overlapping receptor pathways Complementary not redundant Multiple appetite suppression mechanisms Enhanced metabolic effects Potential for greater weight loss than either alone Comparison to proven combinations: CagriSema (semaglutide + cagrilintide): 15-25% proven Tirzepatide alone: 15-22% proven Theoretical tirzepatide + cagrilintide: 20-30% unproven The critical problem: no clinical data What we DON'T know: Is the combination safe
A clinician can review the patients condition, medications, allergies, medical history, lab markers when appropriate, recovery goals, and red flags
Starting low and going slow with dose titration reduces this risk meaningfully
Song J, Zhu K, Wang H, Wu M, Wu Y, Zhang Q